We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

79 hedge funds and large institutions have $250M invested in UroGen Pharma in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 31 increasing their positions, 30 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more call options, than puts

Call options by funds: $4.89M | Put options by funds: $3.55M

3% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 30

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.33% less ownership

Funds ownership: 67.6% → 66.27% (-1.3%)

8% less funds holding

Funds holding: 86 → 79 (-7)

47% less capital invested

Capital invested by funds: $473M → $250M (-$223M)

64% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 11

Holders
79
Holders Change
-7
Holders Change %
-8.14%
% of All Funds
1.74%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
4
Increased
31
Reduced
30
Closed
11
Calls
$4.89M
Puts
$3.55M
Net Calls
+$1.34M
Net Calls Change
+$1.85M

Top Buyers

Rank Fund Capital Flow
1
CI
Clal Insurance
Israel
+$13.8M
2
Artisan Partners
Artisan Partners
Wisconsin
+$8.28M
3
N
Nuveen
North Carolina
+$7.32M
4
PC
Pier Capital
Connecticut
+$4.06M
5
HCM
Horton Capital Management
Pennsylvania
+$3.86M

Top Sellers

Rank Fund Capital Flow
1
HCM
Highline Capital Management
New York
-$16.9M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.41M
3
WCM
Wildcat Capital Management
New York
-$6.91M
4
MIH
Meitav Investment House
Israel
-$6.53M
5
BBA
Baker Bros. Advisors
New York
-$4.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
LC
76
Lindbrook Capital
California
$4K -$1.92K -71 -26%
S
77
SignatureFD
Georgia
$2K -$77.6K -2,872 -96%
Daiwa Securities Group
78
Daiwa Securities Group
Japan
$2K – – –
SPIA
79
Steward Partners Investment Advisory
New York
$1K – – –
Point72 Asset Management
80
Point72 Asset Management
Connecticut
– -$7.41M -222,024 Closed
Simplex Trading
81
Simplex Trading
Illinois
– -$331K -12,262 Closed
ProShare Advisors
82
ProShare Advisors
Maryland
– -$236K -7,077 Closed
State Board of Administration of Florida Retirement System
83
State Board of Administration of Florida Retirement System
Florida
– -$219K -6,570 Closed
PA
84
Parallel Advisors
California
– -$90K -2,700 Closed
Marshall Wace
85
Marshall Wace
United Kingdom
– -$59K -1,769 Closed
CSS
86
Cubist Systematic Strategies
Connecticut
– -$49K -1,478 Closed
QT
87
Quantbot Technologies
New York
– -$48K -1,455 Closed
HCA
88
Horan Capital Advisors
Ohio
– -$33K -1,000 Closed
TRCT
89
Tower Research Capital (TRC)
New York
– -$20K -596 Closed
MAM
90
Meeder Asset Management
Ohio
– -$10K -304 Closed
1 2 3
4

URGN Hedge Fund Activity: Q1 2020 in Review

79 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2020, worth a combined $250M — down 47% from $473M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of URGN and 4 opened new positions — a net loss of 7 holders — while 30 trimmed existing stakes and 31 added.

The largest buyer was Clal Insurance, adding an estimated $13.8M. The largest seller was Highline Capital Management, cutting an estimated $16.9M.

  • 79 institutional investors held UroGen Pharma (URGN) as of Q1 2020, down from 86 in Q4 2019.
  • Funds reported $250M of UroGen Pharma stock for Q1 2020, down 47% quarter-over-quarter.
  • 4 funds opened new UroGen Pharma positions in Q1 2020 and 11 closed out, a net change of -7 holders.
  • The largest UroGen Pharma buyer in Q1 2020 was Clal Insurance, an estimated $13.8M added.
  • The largest UroGen Pharma seller in Q1 2020 was Highline Capital Management, an estimated $16.9M sold.

Based on aggregated 13F filings for Q1 2020.